VITOF Quote, Financials, Valuation and Earnings

Cemex SAB de CV has a net margin of -- compared to Vitro SAB de CV's net margin of 9.92%. Vitro SAB de CV's return on equity of -- beat Cemex SAB de CV's return on equity of 3.67%.

Vitro SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Cemex SAB de CV has an analysts' consensus of $7.78 which suggests that it could grow by 37.43%. Given that Cemex SAB de CV has higher upside potential than Vitro SAB de CV, analysts believe Cemex SAB de CV is more attractive than Vitro SAB de CV.

Vitro SAB de CV has a beta of -19.493, which suggesting that the stock is 2049.291% less volatile than S&P 500. In comparison Cemex SAB de CV has a beta of 1.499, suggesting its more volatile than the S&P 500 by 49.923%.

Vitro SAB de CV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cemex SAB de CV offers a yield of 1.1% to investors and pays a quarterly dividend of $0.02 per share. Vitro SAB de CV pays 23.23% of its earnings as a dividend. Cemex SAB de CV pays out -- of its earnings as a dividend. Vitro SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitro SAB de CV quarterly revenues are --, which are smaller than Cemex SAB de CV quarterly revenues of $4.1B. Vitro SAB de CV's net income of -- is lower than Cemex SAB de CV's net income of $405.7M. Notably, Vitro SAB de CV's price-to-earnings ratio is 2.35x while Cemex SAB de CV's PE ratio is 19.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitro SAB de CV is 0.99x versus 0.48x for Cemex SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.

GCC SAB de CV has a net margin of -- compared to Vitro SAB de CV's net margin of 26.95%. Vitro SAB de CV's return on equity of -- beat GCC SAB de CV's return on equity of 18.06%.

Vitro SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand GCC SAB de CV has an analysts' consensus of -- which suggests that it could fall by --. Given that Vitro SAB de CV has higher upside potential than GCC SAB de CV, analysts believe Vitro SAB de CV is more attractive than GCC SAB de CV.

Vitro SAB de CV has a beta of -19.493, which suggesting that the stock is 2049.291% less volatile than S&P 500. In comparison GCC SAB de CV has a beta of 0.286, suggesting its less volatile than the S&P 500 by 71.362%.

Vitro SAB de CV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GCC SAB de CV offers a yield of 1.01% to investors and pays a quarterly dividend of $0.09 per share. Vitro SAB de CV pays 23.23% of its earnings as a dividend. GCC SAB de CV pays out 8.33% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitro SAB de CV quarterly revenues are --, which are smaller than GCC SAB de CV quarterly revenues of $398.2M. Vitro SAB de CV's net income of -- is lower than GCC SAB de CV's net income of $107.3M. Notably, Vitro SAB de CV's price-to-earnings ratio is 2.35x while GCC SAB de CV's PE ratio is 9.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitro SAB de CV is 0.99x versus 2.20x for GCC SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.

Orbia Advance Corp SAB de CV has a net margin of -- compared to Vitro SAB de CV's net margin of 4.56%. Vitro SAB de CV's return on equity of -- beat Orbia Advance Corp SAB de CV's return on equity of 4.32%.

Vitro SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Orbia Advance Corp SAB de CV has an analysts' consensus of -- which suggests that it could fall by --. Given that Vitro SAB de CV has higher upside potential than Orbia Advance Corp SAB de CV, analysts believe Vitro SAB de CV is more attractive than Orbia Advance Corp SAB de CV.

Vitro SAB de CV has a beta of -19.493, which suggesting that the stock is 2049.291% less volatile than S&P 500. In comparison Orbia Advance Corp SAB de CV has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.927%.

Vitro SAB de CV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orbia Advance Corp SAB de CV offers a yield of 11.03% to investors and pays a quarterly dividend of $0.02 per share. Vitro SAB de CV pays 23.23% of its earnings as a dividend. Orbia Advance Corp SAB de CV pays out -- of its earnings as a dividend. Vitro SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitro SAB de CV quarterly revenues are --, which are smaller than Orbia Advance Corp SAB de CV quarterly revenues of $1.9B. Vitro SAB de CV's net income of -- is lower than Orbia Advance Corp SAB de CV's net income of $86M. Notably, Vitro SAB de CV's price-to-earnings ratio is 2.35x while Orbia Advance Corp SAB de CV's PE ratio is 10.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitro SAB de CV is 0.99x versus 0.19x for Orbia Advance Corp SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.

Grupo Simec SAB de CV has a net margin of -- compared to Vitro SAB de CV's net margin of 36.87%. Vitro SAB de CV's return on equity of -- beat Grupo Simec SAB de CV's return on equity of 17.2%.

Vitro SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Grupo Simec SAB de CV has an analysts' consensus of -- which suggests that it could fall by -55.34%. Given that Grupo Simec SAB de CV has higher upside potential than Vitro SAB de CV, analysts believe Grupo Simec SAB de CV is more attractive than Vitro SAB de CV.

Vitro SAB de CV has a beta of -19.493, which suggesting that the stock is 2049.291% less volatile than S&P 500. In comparison Grupo Simec SAB de CV has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.46%.

Vitro SAB de CV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grupo Simec SAB de CV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vitro SAB de CV pays 23.23% of its earnings as a dividend. Grupo Simec SAB de CV pays out -- of its earnings as a dividend. Vitro SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitro SAB de CV quarterly revenues are --, which are smaller than Grupo Simec SAB de CV quarterly revenues of $451.5M. Vitro SAB de CV's net income of -- is lower than Grupo Simec SAB de CV's net income of $166.5M. Notably, Vitro SAB de CV's price-to-earnings ratio is 2.35x while Grupo Simec SAB de CV's PE ratio is 7.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitro SAB de CV is 0.99x versus 2.25x for Grupo Simec SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.